

- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 21;
- (vi) a binding domain comprising the following six HVRs:
 - (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
 - (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7;
 - (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
 - (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
 - (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
 - (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23;

- (vii) a binding domain comprising the following six HVRs:
 - (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
 - (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7;
 - (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
 - (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 11;
 - (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18; and
 - (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 22;

or

- (viii) a binding domain comprising the following six HVRs:
 - (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
 - (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7;
 - (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
 - (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
 - (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18; and
 - (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25.

In some embodiments, the anti-FcRH5 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8, (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16, and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23.

5 In some embodiments, the binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 104, (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 105, or (c) a VH domain as in (a) and a VL domain as in (b).

10 In some embodiments, the antibody further comprises the

sequence identity to the amino acid sequence of SEQ ID NO: 93, or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the antibody further comprises the following heavy chain variable region FRs: (a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 52, (b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 54, (c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46, and (d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47. In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 92. In some embodiments, the antibody further comprises the following light chain variable region FRs: (a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48, (b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 56, (c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50, and (d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 93. In another aspect, there is provided an anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 92 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 93.

In other embodiments, the anti-FcRH5 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7, (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 11, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 24. In some embodiments, the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 94, (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 95, or (c) a VH domain as in (a) and a VL domain as in (b). In some embodiments, the antibody further comprises the following heavy chain variable region FRs: (a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 52, (b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 54, (c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46, and (d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47. In some embodiments, the VH domain comprises the amino acid sequence of SEQ ID NO: 94. In some embodiments, the antibody further comprises the following light chain variable region FRs: (a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48, (b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 57, (c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50, and (d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51. In some embodiments, the VL domain comprises the amino acid sequence of SEQ ID NO: 95. Disclosed is an anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 94 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 95.

In other embodiments, the anti-FcRH5 antibody comprises a binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7, (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18, and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25. In some embodiments, the binding domain comprises (a) a VH

CR₇ consists of the V133K substitution mutation. In some embodiments, the CR₈ comprises a S183E substitution mutation (EU numbering). In some embodiments, the CR₈ consists of the S183E substitution mutation.

In other embodiments, the VL₂ domain is linked to a CL domain (CL₂) and the VH₂ is linked to a CH1 domain (CH1₂), wherein (a) the CL₂ comprises one or more mutations at amino acid residues F116, L135, S174, S176, and/or T178 (EU numbering) and (b) the CH1₂ comprises one or more mutations at amino acid residues A141, F170, S181, S183, and/or V185 (EU numbering). In some embodiments, the CL₂ comprises one or more of the following substitution mutations: F116A, L135V, S174A, S176F, and/or T178V. In some embodiments, the CL₂ comprises the following substitution mutations: F116A, L135V, S174A, S176F, and T178V. In some embodiments, the CH1₂ comprises one or more of the following substitution mutations: A141I, F170S, S181M, S183A, and/or V185A. In some embodiments, the CH1₂ comprises the following substitution mutations: A141I, F170S, S181M, S183A, and V185A. In some embodiments, the anti-FcRH5 antibody comprises one or more heavy chain constant domains, wherein the one or more heavy chain constant domains are selected from a first CH2 domain (CH2₁), a first CH3 domain (CH3₁), a second CH2 domain (CH2₂), and a second CH3 domain (CH3₂). In some embodiments, at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain. In some embodiments, the CH3₁ and the CH3₂ each comprise a protuberance (P₁) or a cavity (C₁), and wherein the P₁ or the C₁ in the CH3₁ is positionable in the C₁ or the P₁, respectively, in the CH3₂. In some embodiments, the CH3₁ and the CH3₂ meet at an interface between the P₁ and the C₁. In some embodiments, the CH2₁ and the CH2₂ each comprise (P₂) or a cavity (C₂), and wherein the P₂ or the C₂ in the CH2₁ is positionable in the C₂ or the P₂, respectively, in the CH2₂. In some embodiments, the CH2₁ and the CH2₂ meet at an interface between the P₂ and the C₂.

In one aspect, there is provided an anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23; and an anti-CD3 arm comprising a second binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115; (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116; (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121; (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118; (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123.

In another aspect, there is provided an anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8, (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16, and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23, and an anti-CD3 arm comprising a second binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116, (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119, and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123, and wherein the anti-FcRH5 arm and the anti-CD3 arm each comprise an N297G substitution mutation (EU numbering), and wherein the anti-FcRH5 arm comprises a T366W substitution mutation and the anti-CD3 arm comprises T366S, L368A, and Y407V substitution mutations (EU numbering).

In another aspect, there is provided an anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8, (c) an HVR-H3 comprising the

amino acid sequence of SEQ ID NO: 9, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16, and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23, and an anti-CD3 arm comprising a second binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116, (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119, and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123, and wherein the anti-FcRH5 arm comprises a light chain comprising Q38E and V133K substitution mutations and a heavy chain comprising Q39K, S183E, and N297G substitution mutations, and wherein the anti-CD3 arm comprises a light chain comprising Q38K and V133E substitution mutations and a heavy chain comprising Q39E, S183K, and N297G substitution mutations (EU numbering).

Disclosed is an anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises: (a) an anti-FcRH5 arm comprising a first binding domain comprising a VH domain comprising an amino acid sequence of SEQ ID NO: 104 and a VL domain comprising an amino acid sequence of SEQ ID NO: 105, wherein the anti-FcRH5 arm comprises a light chain comprising Q38E and V133K substitution mutations and a heavy chain comprising Q39K, S183E, and N297G substitution mutations, and (b) an anti-CD3 arm comprising a second binding domain comprising a VH domain comprising an amino acid sequence of SEQ ID NO: 133 and a VL domain comprising an amino acid sequence of SEQ ID NO: 134, wherein the anti-CD3 arm comprises a light chain comprising Q38K and V133E substitution mutations and a heavy chain comprising Q39E, S183K, and N297G substitution mutations (EU numbering).

In another aspect, there is provided an anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8, (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16, and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23, and an anti-CD3 arm comprising a second binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116, (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119, and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123, and wherein the anti-FcRH5 arm comprises a light chain comprising Q38K and V133E substitution mutations and a heavy chain comprising Q39E, S183K, and N297G substitution mutations, and wherein the anti-CD3 arm comprises a light chain comprising Q38E and V133K substitution mutations and a heavy chain comprising Q39K, S183E, and N297G substitution mutations (EU numbering).

Disclosed is an anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises: (a) an anti-FcRH5 arm comprising a first binding domain

comprising a VH domain comprising an amino acid sequence of SEQ ID NO: 104 and a VL domain comprising an amino acid sequence of SEQ ID NO: 105, wherein the anti-FcRH5 arm comprises a light chain comprising Q38K and V133E substitution mutations and a heavy chain comprising Q39E, S183K, and N297G substitution mutations, and (b) an anti-CD3 arm comprising a second binding domain comprising a
5 VH domain comprising an amino acid sequence of SEQ ID NO: 133 and a VL domain comprising an amino acid sequence of SEQ ID NO: 134, wherein the anti-CD3 arm comprises a light chain comprising Q38E and V133K substitution mutations and a heavy chain comprising Q39K, S183E, and N297G substitution mutations (EU numbering).

In another aspect, there is provided an anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein
10 the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8, (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16, and (f) an HVR-L3 comprising the amino acid
15 sequence of SEQ ID NO: 23, and an anti-CD3 arm comprising a second binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116, (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119, and (f) an HVR-L3 comprising the
20 amino acid sequence of SEQ ID NO: 123, and wherein the anti-FcRH5 arm comprises a light chain comprising Q38E and V133K substitution mutations and a heavy chain comprising Q39K, S183E, and N297G substitution mutations, and wherein the anti-CD3 arm comprises a light chain comprising Q38K, F116A, L135V, S174A, S176F, and T178V substitution mutations and a heavy chain comprising Q39E, A141I, F170S, S181M, S183A, V185A, and N297G substitution mutations (EU numbering).

Disclosed is an anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody
25 comprises: (a) an anti-FcRH5 arm comprising a first binding domain comprising a VH domain comprising an amino acid sequence of SEQ ID NO: 104 and a VL domain comprising an amino acid sequence of SEQ ID NO: 105, wherein the anti-FcRH5 arm comprises a light chain comprising Q38E and V133K substitution mutations and a heavy chain comprising Q39K, S183E, and N297G substitution mutations, and (b) an anti-
30 CD3 arm comprising a second binding domain comprising a VH domain comprising an amino acid sequence of SEQ ID NO: 133 and a VL domain comprising an amino acid sequence of SEQ ID NO: 134, wherein the anti-CD3 arm comprises a light chain comprising Q38K, F116A, L135V, S174A, S176F, and T178V substitution mutations and a heavy chain comprising Q39E, A141I, F170S, S181M, S183A, V185A, and N297G substitution mutations (EU numbering).

In another aspect, there is provided an anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein
35 the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8, (c) an HVR-H3 comprising the

amino acid sequence of SEQ ID NO: 9, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16, and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23, and an anti-CD3 arm comprising a second binding domain comprising the following six HVRs: (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115, (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116, (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121, (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118, (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119, and (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123, and wherein the anti-FcRH5 arm comprises a light chain comprising Q38K and V133E substitution mutations and a heavy chain comprising Q39E, S183K, and N297G substitution mutations, and wherein the anti-CD3 arm comprises a light chain comprising Q38E, F116A, L135V, S174A, S176F, and T178V substitution mutations and a heavy chain comprising Q39K, A141I, F170S, S181M, S183A, V185A, and N297G substitution mutations (EU numbering).

Disclosed is an anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises: (a) an anti-FcRH5 arm comprising a first binding domain comprising a VH domain comprising an amino acid sequence of SEQ ID NO: 104 and a VL domain comprising an amino acid sequence of SEQ ID NO: 105, wherein the anti-FcRH5 arm comprises a light chain comprising Q38K and V133E substitution mutations and a heavy chain comprising Q39E, S183K, and N297G substitution mutations, and (b) an anti-CD3 arm comprising a second binding domain comprising a VH domain comprising an amino acid sequence of SEQ ID NO: 133 and a VL domain comprising an amino acid sequence of SEQ ID NO: 134, wherein the anti-CD3 arm comprises a light chain comprising Q38E, F116A, L135V, S174A, S176F, and T178V substitution mutations and a heavy chain comprising Q39K, A141I, F170S, S181M, S183A, V185A, and N297G substitution mutations (EU numbering).

In some embodiments of any one of the preceding aspects, the anti-FcRH5 antibody has a clearance following intravenous injection of between about 10 ml/kg/day to about 35 ml/kg/day. In some embodiments, the anti-FcRH5 antibody has a clearance following intravenous injection of about 10 ml/kg/day to about 20 ml/kg/day in a mouse. In some embodiments, the anti-FcRH5 antibody has a clearance following intravenous injection of about 12 ml/kg/day to about 16 ml/kg/day in a mouse. In some embodiments, the anti-FcRH5 antibody has a clearance following intravenous injection of about 20 ml/kg/day to about 40 ml/kg/day in a cyno. In some embodiments, the anti-FcRH5 antibody has a clearance following intravenous injection of about 25 ml/kg/day to about 35 ml/kg/day in a cyno. In some embodiments, the anti-FcRH5 antibody has a clearance following intravenous injection of about 30 ml/kg/day to about 35 ml/kg/day in a cyno.

In another aspect, there is provided one or more isolated nucleic acids encoding an anti-FcRH5 antibody of any one of the preceding aspects, or an antigen-binding fragment thereof.

In another aspect, there is provided one or more vectors comprising the one or more isolated nucleic acids of the previous aspect.

CLAIMS

What is claimed is:

1. An anti-Fc Receptor-like 5 (FcRH5) antibody, wherein the anti-FcRH5 antibody comprises:

(i) a binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23;

(ii) a binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 10;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 14;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23;

(iii) a binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 21;

(iv) a binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 17; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 22;

(v) a binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 13;

- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 21;
- (vi) a binding domain comprising the following six HVRs:
 - (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
 - (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7;
 - (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
 - (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
 - (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
 - (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23;
- (vii) a binding domain comprising the following six HVRs:
 - (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
 - (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7;
 - (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
 - (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 11;
 - (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18; and
 - (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 22; or
- (viii) a binding domain comprising the following six HVRs:
 - (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
 - (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 7;
 - (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
 - (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
 - (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18; and
 - (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 25.

2. The anti-FcRH5 antibody of claim 1(i), wherein the binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 104; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 105; or (c) a VH domain as in (a) and a VL domain as in (b); wherein optionally the antibody further comprises the following heavy chain variable region framework regions (FRs):

- (a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 52;
- (b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 54;
- (c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and
- (d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO: 104; and wherein optionally the antibody further comprises the following light chain variable region FRs:
 - (a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48;

(b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 57;
(c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50; and
(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51, wherein optionally the VL domain comprises the amino acid sequence of SEQ ID NO: 105.

3. An anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 104 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 105.

4. The anti-FcRH5 antibody of claim 1(ii), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 106; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 107; or (c) a VH domain as in (a) and a VL domain as in (b); wherein optionally the antibody further comprises the following heavy chain variable region FRs:

(a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 53;
(b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 54;
(c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and
(d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO: 106; and wherein optionally the antibody further comprises the following light chain variable region FRs:

(a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48;
(b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 57;
(c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50; and
(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51, wherein optionally the VL domain comprises the amino acid sequence of SEQ ID NO: 107.

5. An anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 106 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 107.

6. The anti-FcRH5 antibody of claim 1(iii), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 84; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 85; or (c) a VH domain as in (a) and a VL domain as in (b); wherein optionally the antibody further comprises the following heavy chain variable region FRs:

(a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 52;
(b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 54;
(c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and
(d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47, wherein optionally VH domain comprises the amino acid sequence of SEQ ID NO: 84; and wherein optionally the antibody further comprises the following light chain variable region FRs:

(a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48;
(b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 57;
(c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50; and
(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51, wherein optionally the VL domain comprises the amino acid sequence of SEQ ID NO: 85.

7. An anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 84 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 85.

8. The anti-FcRH5 antibody of claim 1(iv), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 86; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 87; or (c) a VH domain as in (a) and a VL domain as in (b); wherein optionally the antibody further comprises the following heavy chain variable region FRs:

(a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 52;
(b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 54;
(c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and
(d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO: 86; and wherein optionally the antibody further comprises the following light chain variable region FRs:

(a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48;
(b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 57;
(c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50; and
(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51, wherein optionally the VL domain comprises the amino acid sequence of SEQ ID NO: 87.

9. An anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 86 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 87.

10. The anti-FcRH5 antibody of claim 1(v), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 88; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 89; or (c) a VH domain as in (a) and a VL domain as in (b); wherein optionally the antibody further comprises the following heavy chain variable region FRs:

- (a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 52;
- (b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 54;
- (c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and

(d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO: 88; and wherein optionally the antibody further comprises the following light chain variable region FRs:

- (a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48;
- (b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 57;
- (c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50; and

(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51, wherein optionally the VL domain comprises the amino acid sequence of SEQ ID NO: 89.

11. An anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 88 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 89.

12. The anti-FcRH5 antibody of claim 1(vi), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 90; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 91; or (c) a VH domain as in (a) and a VL domain as in (b); wherein optionally the antibody further comprises the following heavy chain variable region FRs:

- (a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 52;
- (b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 54;
- (c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and

(d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO: 90; and wherein optionally the antibody further comprises the following light chain variable region FRs:

- (a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48;
- (b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 57;

(c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50; and
(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51, wherein optionally the VL domain comprises the amino acid sequence of SEQ ID NO: 91.

13. An anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 90 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 91.

14. The anti-FcRH5 antibody of claim 1(vii), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 92; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 93; or (c) a VH domain as in (a) and a VL domain as in (b); wherein optionally the antibody further comprises the following heavy chain variable region FRs:

(a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 52;
(b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 54;
(c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and
(d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO: 92; and wherein optionally the antibody further comprises the following light chain variable region FRs:

(a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48;
(b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 56;
(c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50; and
(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51, wherein optionally the VL domain comprises the amino acid sequence of SEQ ID NO: 93.

15. An anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 92 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 93.

16. The anti-FcRH5 antibody of claim 1(viii), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 96; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 97; or (c) a VH domain as in (a) and a VL domain as in (b); wherein optionally the antibody further comprises the following heavy chain variable region FRs:

(a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 53;

(b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 54;
(c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and
(d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO: 96; and wherein optionally the antibody further comprises the following light chain variable region FRs:

(a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48;
(b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 57;
(c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50; and
(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51, wherein optionally the VL domain comprises the amino acid sequence of SEQ ID NO: 97.

17. An anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 96 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 97.

18. The anti-FcRH5 antibody of claim 1(viii), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 98; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 99; or (c) a VH domain as in (a) and a VL domain as in (b); wherein optionally the antibody further comprises the following heavy chain variable region FRs:

(a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 52;
(b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 55;
(c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and
(d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO: 98; and wherein optionally the antibody further comprises the following light chain variable region FRs:

(a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48;
(b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 57;
(c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50; and
(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51, wherein optionally the VL domain comprises the amino acid sequence of SEQ ID NO: 99.

19. An anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 98 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 99.

20. The anti-FcRH5 antibody of claim 1(viii), wherein the binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 100; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 101; or (c) a VH domain as in (a) and a VL domain as in (b); wherein optionally the antibody further comprises the following heavy chain variable region FRs:

(a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 52;

(b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 54;

(c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and

(d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47, wherein optionally the VH domain comprises the amino acid sequence of SEQ ID NO: 100; and wherein optionally the antibody further comprises the following light chain variable region FRs:

(a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48;

(b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 57;

(c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50; and

(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51, wherein optionally the VL domain comprises the amino acid sequence of SEQ ID NO: 101.

21. An anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain comprising (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 100 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 101.

22. The anti-FcRH5 antibody of any one of claims 1-21, wherein the anti-FcRH5 antibody binds to an epitope in the Ig-like domain 9 of FcRH5; wherein optionally the epitope comprises a portion of amino acids 745-850 of SEQ ID NO: 114.

23. The anti-FcRH5 antibody of claim 22, wherein the binding domain binds to human FcRH5 or cynomolgus monkey (cyno) FcRH5 or both; wherein optionally the binding domain does not specifically bind to FcRH1, FcRH2, FcRH3, and/or FcRH4.

24. The anti-FcRH5 antibody of claim 23, wherein the anti-FcRH5 antibody binds human FcRH5 with a K_D of about 100 nM or lower; wherein optionally the anti-FcRH5 antibody binds human FcRH5 with a K_D of between about 10 pM and about 100 nM; wherein optionally the anti-FcRH5 antibody binds human FcRH5 with a K_D of between about 100 pM and about 100 nM; wherein optionally the anti-FcRH5 antibody binds human FcRH5 with a K_D of between about 1 nM and about 20 nM; and wherein optionally the anti-FcRH5 antibody binds human FcRH5 with a K_D of between about 1 nM and about 10 nM.

25. The anti-FcRH5 antibody of claim 24, wherein the anti-FcRH5 antibody binds cyno FcRH5 with a K_D of about 100 nM or lower; wherein optionally the anti-FcRH5 antibody binds cyno FcRH5 with a K_D of between about 10 pM and about 100 nM; wherein optionally the anti-FcRH5 antibody binds cyno FcRH5 with a K_D of between about 100 pM and about 100 nM; and wherein optionally the anti-FcRH5 antibody binds cyno FcRH5 with a K_D of between about 1 nM and about 50 nM.

26. The anti-FcRH5 antibody of any one of claims 1-25, wherein the anti-FcRH5 antibody comprises a substitution mutation.

27. The anti-FcRH5 antibody of claim 26, wherein the substitution mutation reduces effector function of the anti-FcRH5 antibody.

28. The anti-FcRH5 antibody of claim 26 or 27, wherein the substitution mutation is at amino acid residue N297, L234, L235, D265, and/or P329 (EU numbering); wherein optionally the substitution mutation is selected from the group consisting of N297G, N297A, L234A, L235A, D265A, and P329G; and wherein optionally the substitution mutation is an N297G mutation.

29. The anti-FcRH5 antibody of any one of claims 1-28, wherein the anti-FcRH5 antibody is a monoclonal, human, humanized, or chimeric antibody; wherein optionally the anti-FcRH5 antibody is an IgG antibody.

30. The anti-FcRH5 antibody of any one of claims 1-29, wherein the anti-FcRH5 antibody is an antibody fragment that binds FcRH5; wherein optionally the antibody fragment is selected from the group consisting of bis-Fab, Fab, Fab'-SH, Fv, scFv, and (Fab')₂ fragments; and wherein optionally the antibody fragment is a bis-Fab fragment.

31. The anti-FcRH5 antibody of any one of claims 1-29, wherein the anti-FcRH5 antibody is a full-length antibody.

32. The anti-FcRH5 antibody of any one of claims 1-31, wherein the anti-FcRH5 antibody is (a) a monospecific antibody; or (b) a multispecific antibody.

33. The anti-FcRH5 antibody of claim 32(b), wherein the multispecific antibody is a bispecific antibody.

34. The anti-FcRH5 antibody of claim 33, wherein the bispecific antibody comprises a second binding domain that binds cluster of differentiation 3 (CD3).

35. The anti-FcRH5 antibody of claim 34, wherein the second binding domain binds to an epitope on CD3 comprising amino acid residue Glu6 of CD3.

36. The anti-FcRH5 antibody of claim 35, wherein the epitope further comprises one or more additional amino acid residues selected from the group consisting of Gln1, Asp2, and Met7 of CD3.

37. The anti-FcRH5 antibody of claim 35 or 36, wherein the epitope comprises amino acid residues Gln1, Asp2, and Glu6 of CD3; wherein optionally the epitope comprises amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3; wherein optionally the epitope does not comprise amino acid residue Glu5 of CD3; wherein optionally the epitope does not comprise amino acid residues Gly3 and Glu5 of CD3; and wherein optionally the epitope consists of amino acid residues Gln1, Asp2, Glu6, and Met7 of CD3.

38. The anti-FcRH5 antibody of any one of claims 35-37, wherein the second binding domain is capable of binding to a human CD3 polypeptide or a cyno CD3 polypeptide; wherein optionally the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3 ϵ polypeptide or a cyno CD3 ϵ polypeptide, respectively; or a human CD3 γ polypeptide or a cyno CD3 γ polypeptide, respectively.

39. The anti-FcRH5 antibody of any one of claims 34-38, wherein the second binding domain binds the human CD3 ϵ polypeptide with a K_D of about 100 nM or lower; wherein optionally the second binding domain binds the human CD3 ϵ polypeptide with a K_D of between about 10 pM to about 100 nM; wherein optionally wherein the second binding domain binds the human CD3 ϵ polypeptide with a K_D of between about 100 pM to about 50 nM; and wherein optionally wherein the second binding domain binds the human CD3 ϵ polypeptide with a K_D of between about 1 nM to about 10 nM.

40. The anti-FcRH5 antibody of any one of claims 34-39, wherein the second binding domain comprises the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 117;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 120.

41. The anti-FcRH5 antibody of claim 40, wherein the second binding domain comprises the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123; wherein optionally the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 133; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 134; or (c) a VH domain as in (a) and a VL domain as in (b).

42. The anti-FcRH5 antibody of claim 41, wherein the second binding domain comprises the following heavy chain variable region FRs:

- (a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 125;
- (b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 126;
- (c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 127; and
- (d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 128; wherein optionally the second binding domain comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 133.

43. The anti-FcRH5 antibody of claim 41 or 42, wherein the second binding domain further comprises the following light chain variable region FRs:

- (a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 129;
- (b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 130;
- (c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 131; and
- (d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 132; wherein optionally the second binding domain comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 134.

44. The anti-FcRH5 antibody of any one of claims 41-43, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 133 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 134.

45. The anti-FcRH5 antibody of claim 40, wherein the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 124; wherein optionally the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 137; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 138; or (c) a VH domain as in (a) and a VL domain as in (b).

46. The anti-FcRH5 antibody of claim 45, wherein the second binding domain comprises the following heavy chain variable region FRs:

(a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 125;
(b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 126;
(c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 127; and
(d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 128; wherein optionally the second binding domain comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 137.

47. The anti-FcRH5 antibody of claim 45 or 46, wherein the second binding domain further comprises the following light chain variable region FRs:

(a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 129;
(b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 130;
(c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 131; and
(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 132; wherein optionally the second binding domain comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 138.

48. The anti-FcRH5 antibody of any one of claims 45-47, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 137 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 138.

49. The anti-FcRH5 antibody of any one of claims 34-39, wherein the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 139;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 140;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 141;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 142;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 143; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 144; wherein optionally the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 153; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 154; or (c) a VH domain as in (a) and a VL domain as in (b).

50. The anti-FcRH5 antibody of claim 49, wherein the second binding domain comprises the following heavy chain variable region FRs:

(a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 145;
(b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 146;
(c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 147; and
(d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 148; wherein optionally the second binding domain comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 153.

51. The anti-FcRH5 antibody of claim 49 or 50, wherein the second binding domain further comprises the following light chain variable region FRs:

(a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 149;
(b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 150;
(c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 151; and
(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 152; wherein optionally the second binding domain comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 154.

52. The anti-FcRH5 antibody of any one of claims 49-51, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 153 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 154.

53. The anti-FcRH5 antibody of any one of claims 34-39, wherein the second binding domain comprises the following six HVRs:

(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 155;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 156;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 157;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 158;

- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 159; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 160.

54. The anti-FcRH5 antibody of claim 53, wherein the second binding domain comprises the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 155;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 162;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 157;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 158;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 159; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 160; wherein optionally the second binding domain comprises (a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 172; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 173; or (c) a VH domain as in (a) and a VL domain as in (b).

55. The anti-FcRH5 antibody of claim 54, wherein the second binding domain comprises the following heavy chain variable region FRs:

- (a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 164;
- (b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 165;
- (c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 166; and
- (d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 167; wherein optionally the second binding domain comprises a VH domain comprising the amino acid sequence of SEQ ID NO: 172.

56. The anti-FcRH5 antibody claim 54 or 55, wherein the second binding domain further comprises the following light chain variable region FRs:

- (a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 168;
- (b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 169;
- (c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 170; and
- (d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 171; wherein optionally the second binding domain comprises a VL domain comprising the amino acid sequence of SEQ ID NO: 173.

57. The anti-FcRH5 antibody of any one of claims 54-56, wherein the second binding domain comprises (a) a VH domain comprising an amino acid sequence of SEQ ID NO: 172 and (b) a VL domain comprising an amino acid sequence of SEQ ID NO: 173.

58. The anti-FcRH5 antibody of any one of claims 34-57, wherein the binding domain that binds FcRH5 comprises a VH domain (VH₁) comprising a charged region (CR₁) and a VL domain (VL₁) comprising a charged region (CR₂), wherein the CR₁ in the VH₁ forms a charge pair with the CR₂ in the VL₁; wherein optionally the CR₁ comprises a basic amino acid residue and the CR₂ comprises an acidic amino acid residue; wherein optionally the CR₁ comprises a Q39K substitution mutation (EU numbering); and wherein optionally the CR₁ consists of the Q39K substitution mutation.

59. The anti-FcRH5 antibody of claim 58, wherein the CR₂ comprises a Q38E substitution mutation (EU numbering); wherein optionally the CR₂ consists of the Q38E substitution mutation.

60. The anti-FcRH5 antibody of claim 58 or 59, wherein the second binding domain that binds CD3 comprises a VH domain (VH₂) comprising a charged region (CR₃) and a VL domain (VL₂) comprising a charged region (CR₄), wherein the CR₄ in the VL₂ forms a charge pair with the CR₃ in the VH₂; wherein optionally the CR₄ comprises a basic amino acid residue and the CR₃ comprises an acidic amino acid residue; wherein optionally the CR₄ comprises a Q38K substitution mutation (EU numbering); and wherein optionally the CR₄ consists of the Q38K substitution mutation.

61. The anti-FcRH5 antibody of claim 60, wherein the CR₃ comprises a Q39E substitution mutation (EU numbering); wherein optionally the CR₃ consists of the Q39E substitution mutation.

62. The anti-FcRH5 antibody of any one of claims 58-61, wherein the VL₁ domain is linked to a light chain constant (CL) domain (CL₁) and the VH₁ is linked to a first heavy chain constant (CH1) domain (CH1₁), wherein the CL₁ comprises a charged region (CR₅) and the CH1₁ comprises a charged region (CR₆), and wherein the CR₅ in the CL₁ forms a charge pair with the CR₆ in the CH1₁; wherein optionally the CR₅ comprises a basic amino acid residue and the CR₆ comprises an acidic residue; wherein optionally the CR₅ comprises a V133K substitution mutation (EU numbering); and wherein optionally the CR₅ consists of the V133K substitution mutation.

63. The anti-FcRH5 antibody of any one of claims 62, wherein the CR₆ comprises a S183E substitution mutation (EU numbering); wherein optionally the CR₆ consists of the S183E substitution mutation.

64. The anti-FcRH5 antibody of claim 62 or 63, wherein the VL₂ domain is linked to a CL domain (CL₂) and the VH₂ is linked to a CH1 domain (CH1₂), wherein the CL₂ comprises a charged region (CR₇) and the CH1₂ comprises a charged region (CR₈), and wherein the CR₈ in the CH1₂ forms a charge pair with the CR₇ in the CL₂; wherein optionally the CR₈ comprises a basic amino acid residue and the CR₇ comprises an acidic amino acid residue; wherein optionally the CR₈ comprises a S183K

substitution mutation (EU numbering); and wherein optionally the CR₈ consists of the S183K substitution mutation.

65. The anti-FcRH5 antibody of claim 64, wherein the CR₇ comprises a V133E substitution mutation (EU numbering); wherein optionally the CR₇ consists of the V133E substitution mutation.

66. The anti-FcRH5 antibody of claim 62 or 63, wherein the VL₂ domain is linked to a CL domain (CL₂) and the VH₂ is linked to a CH1 domain (CH1₂), wherein (a) the CL₂ comprises one or more mutations at amino acid residues F116, L135, S174, S176, and/or T178 (EU numbering) and (b) the CH1₂ comprises one or more mutations at amino acid residues A141, F170, S181, S183, and/or V185 (EU numbering); wherein optionally the CL₂ comprises one or more of the following substitution mutations: F116A, L135V, S174A, S176F, and/or T178V; and wherein optionally the CL₂ comprises the following substitution mutations: F116A, L135V, S174A, S176F, and T178V.

67. The anti-FcRH5 antibody of claim 66, wherein the CH1₂ comprises one or more of the following substitution mutations: A141I, F170S, S181M, S183A, and/or V185A; wherein optionally the CH1₂ comprises the following substitution mutations: A141I, F170S, S181M, S183A, and V185A.

68. The anti-FcRH5 antibody of any one of claims 34-57, wherein the binding domain that binds FcRH5 comprises a VH domain (VH₁) comprising a charged region (CR₁) and a VL domain (VL₁) comprising a charged region (CR₂), wherein the CR₂ in the VL₁ forms a charge pair with the CR₁ in the VH₁; wherein optionally the CR₂ comprises a basic amino acid residue and the CR₁ comprises an acidic amino acid residue; wherein optionally the CR₂ comprises a Q38K substitution mutation (EU numbering); and wherein optionally the CR₂ consists of the Q38K substitution mutation.

69. The anti-FcRH5 antibody of claim 68, wherein the CR₁ comprises a Q39E substitution mutation (EU numbering); wherein optionally the CR₁ consists of the Q39E substitution mutation.

70. The anti-FcRH5 antibody of claim 68 or 69, wherein the second binding domain that binds CD3 comprises a VH domain (VH₂) comprising a charged region (CR₃) and a VL domain (VL₂) comprising a charged region (CR₄), wherein the CR₃ in the VH₂ forms a charge pair with the CR₄ in the VL₂; wherein optionally the CR₃ comprises a basic amino acid residue and the CR₄ comprises an acidic amino acid residue; wherein optionally the CR₃ comprises a Q39K substitution mutation (EU numbering); and wherein optionally the CR₃ consists of the Q39K substitution mutation.

71. The anti-FcRH5 antibody of claim 70, wherein the CR₄ comprises a Q38E substitution mutation (EU numbering); wherein optionally the CR₄ consists of the Q38E substitution mutation.

72. The anti-FcRH5 antibody of any one of claims 68-71, wherein the VL₁ domain is linked to a light chain constant (CL) domain (CL₁) and the VH₁ is linked to a first heavy chain constant (CH1) domain (CH1₁), wherein the CL₁ comprises a charged region (CR₅) and the CH1₁ comprises a charged region (CR₆), and wherein the CR₆ in the CH1₁ forms a charge pair with the CR₅ in the CL₁; wherein optionally the CR₆ comprises a basic amino acid residue and the CR₅ comprises an acidic amino acid residue; wherein optionally the CR₆ comprises a S183K substitution mutation (EU numbering); and wherein optionally the CR₆ consists of the S183K substitution mutation.

73. The anti-FcRH5 antibody of claim 72, wherein the CR₅ comprises a V133E substitution mutation (EU numbering); wherein optionally the CR₅ consists of the V133E substitution mutation.

74. The anti-FcRH5 antibody of claim 72 or 73, wherein the VL₂ domain is linked to a CL domain (CL₂) and the VH₂ is linked to a CH1 domain (CH1₂), wherein the CL₂ comprises a charged region (CR₇) and the CH1₂ comprises a charged region (CR₈), and wherein the CR₇ in the CL₂ forms a charged pair with the CR₈ in the CH1₂; wherein optionally the CR₇ comprises a basic amino acid residue and the CR₈ comprises an acidic residue; wherein optionally the CR₇ comprises a V133K substitution mutation (EU numbering); and wherein optionally the CR₇ consists of the V133K substitution mutation.

75. The anti-FcRH5 antibody of claim 74, wherein the CR₈ comprises a S183E substitution mutation (EU numbering); wherein optionally the CR₈ consists of the S183E substitution mutation.

76. The anti-FcRH5 antibody of claim 72 or 73, wherein the VL₂ domain is linked to a CL domain (CL₂) and the VH₂ is linked to a CH1 domain (CH1₂), wherein (a) the CL₂ comprises one or more mutations at amino acid residues F116, L135, S174, S176, and/or T178 (EU numbering) and (b) the CH1₂ comprises one or more mutations at amino acid residues A141, F170, S181, S183, and/or V185 (EU numbering); wherein optionally the CL₂ comprises one or more of the following substitution mutations: F116A, L135V, S174A, S176F, and/or T178V; and wherein optionally the CL₂ comprises the following substitution mutations: F116A, L135V, S174A, S176F, and T178V.

77. The anti-FcRH5 antibody of claim 76, wherein the CH1₂ comprises one or more of the following substitution mutations: A141I, F170S, S181M, S183A, and/or V185A; wherein optionally the CH1₂ comprises the following substitution mutations: A141I, F170S, S181M, S183A, and V185A.

78. The anti-FcRH5 antibody of any one of claims 58-77, wherein the anti-FcRH5 antibody comprises one or more heavy chain constant domains, wherein the one or more heavy chain constant domains

are selected from a first CH2 domain (CH2₁), a first CH3 domain (CH3₁), a second CH2 domain (CH2₂), and a second CH3 domain (CH3₂); wherein optionally at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain; wherein optionally the CH3₁ and the CH3₂ each comprise a protuberance (P₁) or a cavity (C₁), and wherein the P₁ or the C₁ in the CH3₁ is positionable in the C₁ or the P₁, respectively, in the CH3₂; and wherein optionally the CH3₁ and the CH3₂ meet at an interface between the P₁ and the C₁.

79. The anti-FcRH5 antibody of claim 78, wherein P1 comprises a T366W substitution mutation (EU numbering) and/or C1 comprises one or more mutations selected from the group consisting of T366S, L368A, and Y407 substitution mutations (EU numbering).

80. The anti-FcRH5 antibody of claim 78, wherein the CH2₁ and the CH2₂ each comprise (P₂) or a cavity (C₂), and wherein the P₂ or the C₂ in the CH2₁ is positionable in the C₂ or the P₂, respectively, in the CH2₂; wherein optionally the CH2₁ and the CH2₂ meet at an interface between the P₂ and the C₂.

81. An anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23; and

an anti-CD3 arm comprising a second binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123.

82. An anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;

(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
 (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23; and
 an anti-CD3 arm comprising a second binding domain comprising the following six HVRs:
 (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
 (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
 (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121;
 (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
 (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
 (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123; and
 wherein the anti-FcRH5 arm and the anti-CD3 arm each comprise an N297G substitution mutation (EU numbering); and wherein the anti-FcRH5 arm comprises a T366W substitution mutation and the anti-CD3 arm comprises T366S, L368A, and Y407V substitution mutations (EU numbering).

83. An anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23; and

an anti-CD3 arm comprising a second binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123; and

wherein the anti-FcRH5 arm comprises a light chain comprising Q38E and V133K substitution mutations and a heavy chain comprising Q39K, S183E, and N297G substitution mutations; and wherein the anti-CD3 arm comprises a light chain comprising Q38K and V133E substitution mutations and a heavy chain comprising Q39E, S183K, and N297G substitution mutations (EU numbering).

84. An anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;

(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
 (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
 (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
 (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23; and
 an anti-CD3 arm comprising a second binding domain comprising the following six HVRs:
 (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
 (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
 (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121;
 (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
 (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
 (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123; and
 wherein the anti-FcRH5 arm comprises a light chain comprising Q38K and V133E substitution mutations and a heavy chain comprising Q39E, S183K, and N297G substitution mutations; and
 wherein the anti-CD3 arm comprises a light chain comprising Q38E and V133K substitution mutations and a heavy chain comprising Q39K, S183E, and N297G substitution mutations (EU numbering).

85. An anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23; and

an anti-CD3 arm comprising a second binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123; and

wherein the anti-FcRH5 arm comprises a light chain comprising Q38E and V133K substitution mutations and a heavy chain comprising Q39K, S183E, and N297G substitution mutations; and
 wherein the anti-CD3 arm comprises a light chain comprising Q38K, F116A, L135V, S174A, S176F, and T178V substitution mutations and a heavy chain comprising Q39E, A141I, F170S, S181M, S183A, V185A, and N297G substitution mutations (EU numbering).

86. An anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23; and

an anti-CD3 arm comprising a second binding domain comprising the following six HVRs:

- (a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
- (b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
- (c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121;
- (d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
- (e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
- (f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123; and

wherein the anti-FcRH5 arm comprises a light chain comprising Q38K and V133E substitution mutations and a heavy chain comprising Q39E, S183K, and N297G substitution mutations; and wherein the anti-CD3 arm comprises a light chain comprising Q38E, F116A, L135V, S174A, S176F, and T178V substitution mutations and a heavy chain comprising Q39K, A141I, F170S, S181M, S183A, V185A, and N297G substitution mutations (EU numbering).

87. The anti-FcRH5 antibody of any one of claims 1(i), 2, 3, 22-44, and 58-86, wherein the anti-FcRH5 antibody has a clearance following intravenous injection of between about 10 ml/kg/day to about 35 ml/kg/day; wherein optionally the anti-FcRH5 antibody has a clearance following intravenous injection of about 10 ml/kg/day to about 20 ml/kg/day in a mouse; and wherein optionally the anti-FcRH5 antibody has a clearance following intravenous injection of about 12 ml/kg/day to about 16 ml/kg/day in a mouse.

88. The anti-FcRH5 antibody of claim 87, wherein the anti-FcRH5 antibody has a clearance following intravenous injection of about 20 ml/kg/day to about 40 ml/kg/day in a cyno; wherein optionally the anti-FcRH5 antibody has a clearance following intravenous injection of about 25 ml/kg/day to about 35 ml/kg/day in a cyno; and wherein optionally the anti-FcRH5 antibody has a clearance following intravenous injection of about 30 ml/kg/day to about 35 ml/kg/day in a cyno.

89. One or more isolated nucleic acids encoding the anti-FcRH5 antibody of any one of claims 1-88, or an antigen-binding fragment thereof.

90. One or more vectors comprising the one or more isolated nucleic acids of claim 89.
91. One or more host cells comprising the one or more vectors of claim 90.
92. The one or more host cells of claim 91, wherein the one or more host cells is are one or more mammalian host cells, wherein optionally the one or more mammalian host cells are one or more Chinese hamster ovary (CHO) host cells; or one or more prokaryotic host cells, wherein optionally the one or more prokaryotic host cells are one or more *E. coli* host cells.
93. A method of producing the anti-FcRH5 antibody of any one of claims 1-88, the method comprising culturing the one or more host cells of claim 91 in a culture medium.
94. The method of claim 93, wherein the method further comprises recovering the anti-FcRH5 antibody from the one or more host cells or the culture medium.
95. An immunoconjugate comprising the anti-FcRH5 antibody of any one of claims 1-88 and a cytotoxic agent.
96. A composition comprising the anti-FcRH5 antibody of any one of claims 1-88.
97. The composition of claim 96, further comprising a pharmaceutically acceptable excipient or diluent; wherein optionally the pharmaceutically acceptable excipient is a buffer, carrier, stabilizer, or preservative; and wherein optionally the composition is a pharmaceutical composition.
98. The composition of claim 96 or 97, wherein the composition further comprises a PD-1 axis binding antagonist or an additional therapeutic agent.
99. The anti-FcRH5 antibody of any one of claims 1-88 for use as a medicament.
100. Use of the anti-FcRH5 antibody of any one of claims 1-88 or the composition of any one of claims 96-98 in the manufacture of a medicament for treating or delaying progression of an FcRH5-positive cancer in a subject.
101. Use of the anti-FcRH5 antibody of any one of claims 1-88 or the composition of any one of claims 96-98 in the manufacture of a medicament for enhancing immune function in a subject having an FcRH5-positive cancer.

102. The use of claim 100 or 101, wherein the FcRH5-positive cancer is a B cell cancer; wherein optionally the B cell cancer is selected from the group consisting of multiple myeloma (MM), chronic lymphoid leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL); and wherein optionally the B cell cancer is MM.

103. The use of any one of claims 100-102, wherein the anti-FcRH5 antibody binds to (a) an FcRH5 molecule located on a target cell and (b) a CD3 molecule located on an immune effector cell; wherein optionally the anti-FcRH5 antibody activates the immune effector cell following binding to the FcRH5 molecule and the CD3 molecule; wherein optionally the activated immune effector cell is capable of exerting a cytotoxic effect and/or an apoptotic effect on the target cell.

104. The use of claim 103, wherein the target cell is a plasma cell; wherein optionally the plasma cell is a short-lived plasma cell, or a long-lived plasma cell.

105. The use of claim 104, wherein the plasma cell is a myeloma cell.

106. The use of any one of claims 100-105, wherein the anti-FcRH5 antibody is to be administered to the subject at a dosage of about 0.01 mg/kg/wk to about 50 mg/kg/wk; wherein optionally the anti-FcRH5 antibody is to be administered to the subject at a dosage of about 0.1 mg/kg/wk to about 10 mg/kg/wk; and wherein optionally the anti-FcRH5 antibody is to be administered to the subject at a dosage of about 1 mg/kg/wk.

107. The use of any one of claims 100-106, wherein the medicament is to be administered with a PD-1 axis binding antagonist and/or an additional therapeutic agent; wherein optionally the PD-1 axis binding antagonist or additional therapeutic agent is to be administered prior to or subsequent to the administration of the anti-FcRH5 antibody; and wherein optionally the PD-1 axis binding antagonist or additional therapeutic agent is to be administered concurrently with the anti-FcRH5 antibody.

108. The use of claim 107, wherein the PD-1 axis binding antagonist is selected from the group consisting of a PD-L1 binding antagonist, a PD-1 binding antagonist, and a PD-L2 binding antagonist.

109. The use of claim 108, wherein the PD-1 axis binding antagonist is a PD-L1 binding antagonist; wherein optionally the PD-L1 binding antagonist is selected from the group consisting of MPDL3280A (atezolizumab), MDX-1105, MEDI4736 (durvalumab), and MSB0010718C (avelumab); and wherein optionally the PD-L1 binding antagonist is MPDL3280A (atezolizumab).

110. The use of claim 108, wherein the PD-1 axis binding antagonist is (i) a PD-1 binding antagonist, wherein optionally the PD-1 binding antagonist is selected from the group consisting of MDX 1106

(nivolumab), MK-3475 (pembrolizumab), MEDI-0680 (AMP-514), PDR001, REGN2810, and BGB-108; or (ii) a PD-L2 binding antagonist, wherein optionally the PD-L2 binding antagonist is an antibody or an immunoadhesin.

111. The use of any one of claims 100-110, wherein the medicament is to be administered with a steroid, an immunomodulator (IMiD), a proteasome inhibitor (PI), or a combination thereof; wherein optionally (i) the steroid is a glucocorticoid, wherein optionally the glucocorticoid is dexamethasone; (ii) the IMiD is lenalidomide; or (iii) the PI is bortezomib.

112. The use of any one of claims 100-111, wherein the anti-FcRH5 antibody, PD-1 axis binding antagonist, steroid, IMiD, PI, or combination thereof is to be administered intravenously, subcutaneously, intramuscularly, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally.

113. The use of claim 112, wherein the anti-FcRH5 antibody, PD-1 axis binding antagonist, steroid, IMiD, PI, or combination thereof is to be administered intravenously or subcutaneously.

114. The use of any one of claims 100-113, wherein the subject is a human.

115. A method for detecting FcRH5 in a biological sample from a subject, wherein the method comprises:

(a) contacting the biological sample with the anti-FcRH5 antibody of any one of claims 1-88 under conditions permissive for binding of the anti-FcRH5 antibody to a naturally occurring FcRH5 in the biological sample, and

(b) detecting whether a complex is formed between the anti-FcRH5 antibody and a naturally occurring FcRH5 in the biological sample.

116. The method of claim 115, wherein the biological sample is a blood sample.

117. The method of claim 115 or 116, wherein the subject is a human.

118. A kit comprising the antibody of any one of claims 1-88 and a package insert comprising instructions for using the antibody for treating or delaying progression of an FcRH5-positive cancer in a subject.

119. A kit comprising the antibody of any one of claims 1-88 and a package insert comprising instructions for using the antibody for enhancing immune function in a subject having an FcRH5-positive cancer.

120. The kit of claim 118 or 119, wherein the subject is a human.